Brain Diseases Portfolio
Provider 
Founded 1915
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public

Lundbeck's portfolio of registered therapies for neurological and psychiatric brain diseases, marketed across more than 80 countries.
Lundbeck's product portfolio spans brain diseases, with registered products in more than 80 countries. Its neurological disorder offerings include therapies for Parkinson's disease (Azilect, rasagiline), alcohol dependence (Selincro, nalmefene), Alzheimer's disease (Ebixa, memantine), migraine (Vyepti, eptinezumab), and epilepsy (Sabril, vigabatrin, and Onfi, clobazam).
Its psychiatric disorder offerings address depression, anxiety, and psychosis, led by brexpiprazole (Rexulti, Rxulti), vortioxetine (Brintellix, Trintellix), escitalopram (Cipralex, Lexapro), citalopram (Cipramil, Celexa), and long-acting antipsychotic formulations including Abilify Maintena (aripiprazole) and zuclopenthixol depots. The portfolio also includes Northera (droxidopa) within its other-diseases group.
| Attribute | Brain Diseases Portfolio | Exeltis — Central Nervous System | |
|---|---|---|---|
| Provider | |||
| Founded | 1915 | 2003 | |
| Sells To | Enterprise | — | |
| Pricing Model | Recurring, Software | — | |
| Ownership | Public | — |
Provider 
Founded 1915
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public
Provider 
Founded 2003
Sells To —
Pricing Model —
Ownership —


Supernus commercial portfolio of products treating neurological and psychiatric conditions including ADHD, epilepsy, Parkinson's disease, and migraine.


Central nervous system portfolio covering antidepressants, anticonvulsants, migraine, ADHD, and neurodegeneration medicines.
UCB's solutions line addressing neurological and autoimmune conditions, delivered through its global biopharmaceutical portfolio.
Supernus commercial portfolio of products treating neurological and psychiatric conditions including ADHD, epilepsy, Parkinson's disease, and migraine.

Central nervous system portfolio covering antidepressants, anticonvulsants, migraine, ADHD, and neurodegeneration medicines.

UCB's solutions line addressing neurological and autoimmune conditions, delivered through its global biopharmaceutical portfolio.